Title (en)
  GLUCAGON-LIKE PEPTIDE 1(GLP-1) PHARMACEUTICAL FORMULATIONS

Title (de)
  PHARMAZEUTISCHE GLUCAGON-ÄHNLICHE PEPTID1-FORMULIERUNGEN

Title (fr)
  FORMULATIONS PHARMACEUTIQUES À PEPTIDE APPARENTÉ AU GLUCAGON 1(GLP-1)

Publication
  EP 2010155 A2 20090107 (EN)

Application
  EP 07760728 A 20070416

Priority
  • US 2007066728 W 20070416
  • US 74488206 P 20060414

Abstract (en)
  [origin: WO2007121411A2] A composition is disclosed comprising glucagon- like peptide 1 (GLP-I) particles in combination with diketopiperazine
  (DKP) that is stable both in vitro and in vivo. The composition has utility as a pharmaceutical formulation for treating diseases such as diabetes,
  cancers, and obesity but is not limited to such diseases or conditions. In particularly, the composition has utility as a pharmaceutical formulation for
  pulmonary delivery.

IPC 8 full level
  A61K 9/16 (2006.01); **A61K 38/26** (2006.01)

CPC (source: EP KR)
  A61K 9/0019 (2013.01 - EP); **A61K 9/0073** (2013.01 - KR); **A61K 9/0075** (2013.01 - EP KR); **A61K 9/08** (2013.01 - EP);
  A61K 9/143 (2013.01 - EP); **A61K 9/145** (2013.01 - EP); **A61K 9/16** (2013.01 - KR); **A61K 9/1611** (2013.01 - KR); **A61K 9/1682** (2013.01 - KR);
  A61K 9/19 (2013.01 - KR); **A61K 31/496** (2013.01 - KR); **A61K 38/26** (2013.01 - EP KR); **A61K 45/06** (2013.01 - EP); **A61P 1/00** (2017.12 - EP);
  A61P 1/04 (2017.12 - EP); **A61P 1/18** (2017.12 - EP); **A61P 3/00** (2017.12 - EP); **A61P 3/04** (2017.12 - EP); **A61P 3/06** (2017.12 - EP);
  A61P 3/10 (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 25/28** (2017.12 - EP);
  A61P 35/00 (2017.12 - EP); **A61P 37/06** (2017.12 - EP); **A61P 43/00** (2017.12 - EP)

Citation (search report)
  See references of WO 2007121411A2

Designated contracting state (EPC)
  AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

Designated extension state (EPC)
  AL BA HR MK RS

DOCDB simple family (publication)
  WO 2007121411 A2 20071025; **WO 2007121411 A3 20071213**; AU 2007238000 A1 20071025; AU 2007238000 B2 20130117;
  BR PI0709964 A2 20110802; CA 2646400 A1 20071025; CN 101453988 A 20090610; CN 104288756 A 20150121; EP 2010155 A2 20090107;
  HK 1206241 A1 20160108; JP 2009533476 A 20090917; JP 2014043445 A 20140313; JP 2016104736 A 20160609; JP 5415938 B2 20140212;
  JP 5898156 B2 20160406; KR 101438839 B1 20141002; KR 101558829 B1 20151008; KR 20080111533 A 20081223;
  KR 20140072138 A 20140612; KR 20150042304 A 20150420; MX 2008013216 A 20081027; RU 2008144965 A 20100520;
  RU 2010137392 A 20120320; RU 2014152320 A 20160720; RU 2409349 C2 20110120; RU 2542500 C2 20150220

DOCDB simple family (application)
  US 2007066728 W 20070416; AU 2007238000 A 20070416; BR PI0709964 A 20070416; CA 2646400 A 20070416;
  CN 200780013424 A 20070416; CN 201410514033 A 20070416; EP 07760728 A 20070416; HK 15106772 A 20150716;
  JP 2009505655 A 20070416; JP 2013191549 A 20130917; JP 2015233125 A 20151130; KR 20087027774 A 20070416;
  KR 20147011316 A 20070416; KR 20157008571 A 20070416; MX 2008013216 A 20070416; RU 2008144965 A 20070416;
  RU 2010137392 A 20070416; RU 2014152320 A 20141223